ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Aldeyra Therapeutics Inc

Aldeyra Therapeutics Inc (ALDX)

1,63
-0,13
(-7,39%)
Geschlossen 07 Juni 10:00PM
1,72
0,09
(5,52%)
Nach Börsenschluss: 1:57AM

Aldeyra Therapeutics Inc (ALDX) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
1,72
( -2,27% )
Gebot
1,42
Fragen
2,12
Volumen
981.471
1,615 Tagesbereich 1,76
1,07 52-Wochen-Bereich 6,175
Marktkapitalisierung
Handelsende
1,76
Handelsbeginn
1,76
Letzter Handelszeitpunkt
Finanzvolumen
US$ 1.636.819
VWAP
1,6677
Durchschnittliches Volumen (3 Mio.)
US$ 3.146.839
Ausgegebene Aktien
60.321.068
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-3,76
Gewinn pro Aktie (EPS)
-0,45
Erlöse (LTM)
-
Nettogewinn (LTM)
-27,37M

Über Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and alle... Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Website
Hauptsitz
Lexington, United States
Gegründet
2026
Aldeyra Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker ALDX. The last closing price for Aldeyra Therapeutics was US$1,76. Over the last year, Aldeyra Therapeutics shares have traded in a share price range of US$ 1,07 to US$ 6,175.

Aldeyra Therapeutics currently has 60.321.068 shares in issue. The market capitalisation of Aldeyra Therapeutics is US$103,75 million. Aldeyra Therapeutics has a price to earnings ratio (PE ratio) of -3.76.

ALDX Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
1-0.02-1.149425287361.741.931.5810799931.76057551CS
40.021.176470588241.71.931.5059894641.70483631CS
12-2.97-63.32622601284.694.721.0731813511.68190815CS
26-3.16-64.75409836074.885.931.0720770252.6160414CS
52-0.74-30.0813008132.466.1751.0714749193.30438731CS
156-8.94-83.864915572210.6611.971.0711941493.71521944CS
260-11-86.477987421412.7213.181.0710228984.54507796CS

ALDX - Frequently Asked Questions (FAQ)

What is the current Aldeyra Therapeutics Inc share price?
The current share price of Aldeyra Therapeutics Inc is US$ 1,72
How many Aldeyra Therapeutics Inc shares are in issue?
Aldeyra Therapeutics Inc has 60.321.068 shares in issue
What is the market cap of Aldeyra Therapeutics Inc?
The market capitalisation of Aldeyra Therapeutics Inc is USD 103,75M
What is the 1 year trading range for Aldeyra Therapeutics Inc share price?
Aldeyra Therapeutics Inc has traded in the range of US$ 1,07 to US$ 6,175 during the past year
What is the PE ratio of Aldeyra Therapeutics Inc?
The price to earnings ratio of Aldeyra Therapeutics Inc is -3,76
What is the registered address of Aldeyra Therapeutics Inc?
The registered address for Aldeyra Therapeutics Inc is 131 Hartwell Avenue, Lexington, Massachusetts, 02421
What is the Aldeyra Therapeutics Inc website address?
The website address for Aldeyra Therapeutics Inc is www.aldeyra.com
Which industry sector does Aldeyra Therapeutics Inc operate in?
Aldeyra Therapeutics Inc operates in the Biotechnology & Life Sciences sector

ALDX Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen